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China as an ‘Emerging Biotech Power’ 
 
By Ayo Wahlberg, Department of Anthropology, University of Copenhagen 
 
Abstract 
Asia’s dramatic entry on to the global biotech scene has not gone unnoticed by commentators and 
social scientists alike. Countries like China, India, South Korea and Singapore have been identified 
as ‘emerging biotech powers’. Consequently, scholars have begun examining the particularities of 
how biotechnologies (e.g. stem cell science, genetic testing and reproductive medicine) have come 
to be taken up and grounded in a variety of cultural, legal and socio-economic contexts. They have 
also examined how governments, scientists, clinicians and others have been engaged in efforts to 
build up endogenous biotech sectors as a part of nation building strategies. In this paper, rather 
than attempting to answer questions of what makes biotechnology particularly Asian, I will instead 
investigate how demarcations and boundaries are mooted in global negotiations of what 
constitutes ‘good’ biotechnology. The analysis is based on a collaborative project between Chinese 
and European scientists and experts on the ethical governance of biomedical and biological 
research. I show how an underlying condition for the negotiations that took place within this 
collaboration was the proposition that difference matters when it comes to developing, organising, 
carrying out and overseeing biotechnological research in a particular country. 
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Introduction 
At a workshop on ethical challenges surrounding stem cell research held in Shanghai in 2007, one 
of the presenters projected an introductory slide on to the screen behind him with the words 
“Open in 2009” in bold. The backdrop of the slide was an architect’s portrayal of a spectacular new 
biomedical research complex under construction in the south of China. The presenter had recently 
returned to China from the USA to head up a team of embryonic stem cell researchers at this new 
research centre. Other presenters had similar slides, and during discussions, the mood of the 
workshop was captured in the reflections of one workshop participant: “One of the characteristics 
of Chinese policies on stem cell research is the ambition to be a power in bioscience and 
biotechnology. A huge amount of resources invested in it”. A year later, during a site visit to a 
biotechnology research institution at another workshop in Shenzhen, participants were introduced 
to an impressive wall display featuring several Nature cover stories stemming from their research. 
Following a guided tour of the institute filled with numerous multi-million-dollar DNA sequencing 
and digital data storage machines, we each received a postcard featuring a cartoon of a staff 
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member answering an awed group of international visitors (like ours) – “Wow so many 
machines!” – with a deadpanned “It’s still not enough”. 
 
In recent years, a string of publications have analysed Asia’s dramatic entry on to a global biotech 
scene1. State-led investment programmes, turning brain-drain into brain-gain by luring back young 
researchers from Europe and America, political mobilisation around biotechnology as a potential 
engine of economic growth, nationalist aspirations in a global race ‘to be the first’ as well as 
anxieties surrounding biosecurity risks have all been highlighted as catalysts of “Asia’s Rising 
Science and Technology Strength”2. With titles and sub-titles like ‘Biopolitics in Asia’, ‘Biopolitics in 
China’, ‘Asian Biotech’ and ‘imagining biotech India’, one of the common tasks of this literature 
has been to examine whether there is something particular to biotechnology in Asia, or indeed 
whether there is something which might qualify as Asian biotechnology (presumably as opposed 
to Western). 
 
In a special issue of New Genetics and Society on the theme of ‘Biopolitics in Asia’, Herbert 
Gottweis suggests that “despite all general trends towards globalization a distinctive picture of 
biopolitics in Asia is in the process of emerging… Asia today is neither a ‘Wild East’ nor simply, one 
big, research and experimental population in the service of the global bioeconomy”3. Instead, 
contributors to the special issue show how governments, scientists and others are engaged in 
‘bionational’ efforts to build up endogenous biotech sectors. In a similar vein, Bharadwaj has 
argued that in the context of the rise of neo-India in a global biotechnology sector, “the twentieth-
century development discourse which privileged the unidirectional flow of knowledge from the 
‘global’ North/developed to the ‘local’ South/developing is now both an untenable orthodoxy and 
an unsustainable project”4. The point being that we need to approach these developments in India 
and other Asian countries as ‘biotechnological autoproduction’ rather than ‘mere’ technology 
transfer. Ong and Chen, on the other hand, shift focus from what is happening in Asia to the 
question of what it is that makes biotechnology Asian. ‘Asian biotech’, they suggest, denotes a 
“historical moment when biotechnologies articulate powerful nationalist aspirations in newly 
affluent Asia” as contributors to their volume show how biotechnology harnesses and aligns with 
ongoing nation-building efforts thereby palpably contributing to the negotiation and production of 
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‘Asianness’5. For example, in a chapter on ‘Chinese DNA’ Wen-Ching Sung shows how the 
“introduction of genomics since the 1990s… adds another spin to the discourses and practices on 
China’s ethnic categorization”6, while Charis Thompson analyses the ‘Koreanness’ of fallen stem 
cell scientist Hwang Woo Suk who had suggested that dexterous Korean chop stick users had 
sharpened the cell work done in his laboratory7. 
 
In this article, I will show how difference is actively mobilised on a global scale in the realm of 
biotechnology. Rather than attempting to answer this question of what makes/when is 
biotechnology particularly Asian, I will instead investigate how demarcations and boundaries are 
mooted in global negotiations of what constitutes ‘good’ biotechnology. Through his studies of 
mobilisation practices among indigenous activists of the Colombian Pacific, Arturo Escobar has 
argued that an important way in which a politics of difference plays out is in struggles against the 
terms of globality. “[P]eople mobilize against the destructive aspects of globalization from the 
perspective of what they have been and what they are at present... in the defense of place from 
the perspective of the economic, ecological, and cultural difference that their landscapes, cultures, 
and economies embody in relation to those of more dominant sectors of society”8. Indeed, as 
noted in the introduction to this special issue, ‘difference’ has analytically often been used in 
contexts of resistance, as a way to circumvent hegemonies and hierarchies and to stake claims 
‘from below’. My analysis will show how difference can also be mobilized by ‘dominant sectors of 
society’, in my case the biotech sector, in the making of the figure of an ‘emerging biotech power’. 
That is to say, the mobilisation of difference is not something restricted to emancipatory struggles 
against dominance, but can also be found in concrete contexts of nation-building led by scientists, 
government officials, lawyers and other experts. 
 
The context within which I will examine this field of problematisation is that of an international 
collaborative project between Chinese and European social and natural scientists that took place 
over a three-year period (2006-2009) called BIONET9. Over the course of these years I participated 
in and helped to organise a series of 6 workshops and conferences, five of which took place in 
China (Beijing, Shanghai, Changsha, Xian and Shenzhen)10. These events focused on ethical 
challenges surrounding the governance of biomedical research involving volunteer human subjects 
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in the fields of stem cell research, clinical trials and genomics and were attended by more than 300 
leading life scientists, ethicists, lawyers, social scientists as well as government representatives 
from China and Europe. Simultaneous translation was provided for European and Chinese 
participants at each of these events and presentations and discussions were recorded and 
summarised in workshop reports. The objective of these events was to map out practices of 
ethical governance of biomedical and biological research in China and Europe. The following 
analysis is based on my attendance and participation in these events (including my field notes), 
informal discussions with participants during lunches and dinners as well as the reports that were 
prepared during the course of the project. I have read through my field notes, copies of 
presentation slides as well as the workshop reports to identify common themes and issues. As 
such what follows is an analysis of one particular forum of global negotiation of difference. 
 
I begin the article by asking what kind of biotechnology it is we are talking about that apparently 
can be characterised in terms of particular national or regional traits – namely a global 
biotechnology. I then move on to analyse how difference was explicitly mobilised during the 
course of the workshop and conference presentations and discussions which all addressed in some 
way the question of what makes biotechnological research ‘ethical’. I focus in particular on two 
kinds of difference that were consistently brought up during the project over the three years. 
Firstly, a kind of carving out of a competitive advantage niche and secondly, debates around 
whether bioethics are universal and if so whether that allows space for an ‘Asian bioethics’ or 
indeed ‘Chinese bioethics’. I conclude by reflecting on how difference helps us to think about 
global biotechnology. 
 
Global biotechnology 
 
There is nothing particularly ‘new’ about life sciences research, not even about some of the much-
hyped 21st-century fields of genomics or regenerative medicine. Both have long histories dating 
back decades. Yet new developments are of course happening within these fields, many of which 
are linked to ongoing technological developments on the one hand, and globalisation processes on 
the other. A ‘molecular gaze’ has emerged out of the life sciences propelled by high-powered 
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microscopy and imaging technologies as well as the development of DNA sequencing techniques 
and associated bioinformatics computing software11. At the same time, life science has become 
mobile as scientists, biological samples, digital information databases, technologies and 
biomedical treatments travel across national and continental borders. A biological sample 
procured in one place can be FedExed across the world to be sequenced and chemically analyzed 
and the information derived can be electronically transmitted to relevant parties around the world. 
A biomedical treatment developed in Switzerland can be transported to China for clinical testing 
on Chinese volunteers before being approved for use on American citizens. Immortalised stem cell 
lines can be ordered online from various stem cell banks and shipped globally. And so forth. 
 
Yet this globalisation of biotechnological research has raised numerous questions about the ethics 
of such endeavours. According to which standards should such research be judged? Whose ethical 
guidelines and regulations are applicable in situations where Chinese and European scientists 
collaborate? Which safeguards should be put in place to avoid exploitation of vulnerable patients 
and populations? These are not logistical questions concerning how best to organize scientific 
collaboration projects most efficiently, rather they are questions which concern what it is that 
makes particular forms of research ‘ethical’. 
 
It is with these kinds of questions that the Sino-European project which I took part in engaged. As 
such, the presentations and discussions that I observed were characterised by exchanges between 
Chinese and European scientists and experts regarding how to go about ensuring that 
biotechnological research was ethical when multiple languages, cultural backgrounds, socio-
economic contexts, regulatory traditions and the like were at stake. The common point of 
departure was that for biotechnological research requiring volunteer human subjects (such as 
stem cell research, genomic research and clinical trials) to be ‘good’ not only did it have to be 
scientifically rigorous and efficiently organised, it also had to be ‘ethically sound’. Yet despite the 
existence of such global reference documents as the Helsinki Declaration on Ethical Principles for 
Medical Research Involving Human Subjects or the Universal Declaration on Bioethics and Human 
Rights, there was plenty of room for interpretation and negotiation as to how such universal 
principles might apply in particular contexts. It is on the basis of my observations of such 
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negotiations between workshop participants that I present the following analysis of difference in 
global biotechnology12. What I will show is how an underlying condition for such negotiations to 
take place was the proposition that difference matters when it comes to developing, organising, 
carrying out and overseeing biotechnological research in a particular country. 
 
Many different Chinas 
 
Let us begin with the question of how can biotechnological research be organised, carried out and 
overseen in China? As noted in the opening of this article, there can be no question about the 
stated ambition of political leaders, government officials and scientists that China become a so-
called ‘global player’ in biotechnology. This ambition has been backed up by state investment 
programmes, new laboratory facilities as well as regulatory reforms. And one can already discern 
the results of this strategy in the form of one of the world’s largest genome sequencing centres, an 
increasing number of published articles in renowned life science journals stemming from research 
units in China as well as a sharp increase in the number of international research collaborations 
involving Chinese partners13. 
 
Just as Sunder Rajan has shown how numerous actors are currently “building clinical research 
infrastructure in India [while] also promoting India as a clinical trial destination globally”14, the 
same can be said of China. Indeed, in 2007, a report by the Financial Times suggested that 274 of 
those clinical trials registered on the US government’s clinicaltrials.gov were being carried out in 
China while 260 were being carried out in India15. At a workshop held in Xian, a senior medical 
college representative proclaimed that “we welcome more clinical trials in China, we are ready”. In 
the workshop discussions, the ‘attractive’ characteristics of China as a clinical trials destination 
were debated. Clinicians and other experts pointed out that the country had a large population 
and relatively easy patient recruitment, it had good quality medical and research infrastructure at 
substantially lower costs, and perhaps most importantly, a growing domestic pharmaceuticals 
market. Yet not only have government officials, scientists, companies and other actors been 
engaged in building up a physical clinical research infrastructure, over the last decade or so, they 
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have also been engaged in the building up of what Reubi has referred to as the ‘soft infrastructure’ 
of biomedical research ethics16. As pointed out by a lawyer in our Shanghai workshop,  
“almost every bioethical aspect regarding biomedical manipulations has been addressed to 
protect the rights of human subjects and public morality”. He was referring to a flurry of ethical 
guidelines, regulations and norms that have been promulgated by both the Ministry of Health and 
the Ministry of Science and Technology in recent years regarding extraction and export of genetic 
resources (1998), stem cell research (2003), Good Clinical Practice (2003), scientific integrity and 
misconduct (2007), ethical review of biomedical research involving human subjects (2007) and 
more. Such an infrastructure of biomedical ethics was deemed necessary by some participants, 
not least as a way to counter misguided assumptions that “the development of biomedical 
research and biotechnology without constraint or unbounded freedom will allow China to more 
rapidly catch up with efforts in developed nations”. The scandal surrounding and reputational 
damage caused by Korean stem cell scientist Hwang Woo Suk was raised in many presentations 
and discussions as a kind of warning: “Chinese science and technology could lose its essential 
integrity and public support both at home and abroad. The scandals over Hwang Woo Suk in 
[South] Korea and Chen Jin17 in China convincingly illustrate this point”. 
 
Yet the China that was being assembled in these accounts was very much that of elite centres of 
excellence which had the resources and capacity to carry out large scale scientific research 
projects in accordance with international and national ethical guidelines. Other workshop 
participants were quick to point out a marked lack of capacity in many of the clinics and 
laboratories found in smaller cities, with some suggesting that one should indeed differentiate 
between high capacity centres of excellence and those lagging behind. Evoking anthropologist 
Adriana Petryna’s notion of ‘ethical variability’18 one participant commented: “China is a big 
country. Implementation of ethical regulations varies drastically among regions and institutes. This 
situation may not be easily changed in a short time”.  There were, in other words, many different 
Chinas within China with access to vastly different amounts of resources, and when the case was 
made for China as an ‘attractive’ biotechnological research destination, this attraction was very 
specific to certain centres. An important point raised by numerous speakers concerned the gaps 
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that remained between regulations and guidelines on the one hand and the situation on the 
ground in many clinics and laboratories on the other. 
 
Biomedical research infrastructure was not the only attraction that was flagged by participants at 
our many workshops. One of China’s perhaps most internationally notorious features is its large 
population of some 1.2 billion people. This was an advantage, it was suggested, not only in terms 
of recruitment of volunteers into biomedical research, it also represented a kind of ‘treasure trove’ 
of, on the one hand, genetic diversity, and on the other a diverse disease profile (from infectious 
to lifestyle diseases), both of which were ‘available’, waiting to be researched upon. In a workshop 
on biobanking, a senior scientist explained how “there are 56 ethnic groups in China, each of them 
having independent inhabitation areas and some of them are genetically isolated as populations. 
In terms of genetic phenotypes, each ethnic group has its unique characteristics. There are 
significant differences in categories, enzyme systems, HLA antigens and incidences of some 
genetic diseases.” One could therefore take biomedical advantage from the ‘homogenous’ 
marrying habits of particular cultural groups within China, but the task was urgent he pointed out 
since “at present, more and more youths are marrying across different nationalities, and as a 
result the genomes of some nationalities face the danger of extinction”. 
 
Yet, as already pointed out, it was not only the genetic diversity of China’s 56 ethnic groups that 
was described as a valuable and ‘attractive’ research resource, the fact that China was in the midst 
of massive socio-economic transformation meant that China’s population was host to a diversity 
of diseases which made it especially conducive to medical genomic research. For example, when 
introducing a large scale prospective cohort study aiming to determine environmental risk factors, 
life course causes and genetic risk factors underlying common chronic diseases, one of the 
project’s scientists explained the reasoning behind choosing the city of Taizhou as their study site: 
“Why Taizhou? Well, it is located in the area connecting north and south China with an admixture 
of northern and southern populations. The population is right at the start of economic 
transformation and it is a well-established site for epidemiology studies with strong local 
government support”. 
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While there are clear similarities between for example, China and India, what I am suggesting here 
is that an important component of the casting of China as an ‘emerging biotech power’ has been 
the carving out of a competitive advantage niche that sets China apart, in particular, from the 
‘West’. Difference here, sets China apart in terms of the relatively low cost of its otherwise high 
quality biomedical research infrastructure but also in terms of its biological ‘assets’, which in turn 
parcels out different groups and areas within China in terms of genetic diversity and a diverse 
disease profile. So, not only is China’s attractiveness as a biotech research site related to its 
difference from the West, but also to differences (or diversity) within China19. 
 
Overseeing biomedical research in China 
 
What bound the various forms of biotech research covered in our workshops together was their 
reliance on volunteer human subjects, either as donors of biological samples (e.g. blood samples 
for genomic research or ‘leftover embryos’ from fertility treatment for stem cell research) and 
associated biographical data (e.g. about lifestyle, family medical history, socio-economic 
background) or as recipients of experimental therapies (e.g. new pharmaceuticals or stem cell 
therapies). As such these were forms of research which required not just scientific oversight in the 
form of peer review but also ethical oversight in the form of ethical review. The point being, as 
noted earlier, that for scientific research requiring volunteer human subjects to be ‘good’ not only 
did it have to be scientifically rigorous it also had to be ethically sound. 
 
There is a growing critical literature on the shortcomings of what is sometimes referred to as 
‘global’ bioethics, understood as a universalised and instrumentalised set of principles and 
practices aimed at safeguarding and protecting those individuals who voluntarily participate in 
biomedical research20. For the purposes of this paper I will not engage with this literature, I will 
instead show how during often lively debates about the ways in which ethical oversight of 
biomedical research should be organised, cultural and socio-economic differences were mobilised. 
There are two particular debates that I will recount in this section: the first concerns a debate 
between European and Chinese scientists about the moral status of an embryo in the context of 
human embryonic stem cell research, and the second concerns debates about the different forms 
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of interaction between researchers and volunteer human subjects that should or should not be 
allowed. 
 
Chinese values 
 
One of the most vocally contested areas of stem cell research worldwide has been that of human 
embryonic stem cell (hESC) research. Such research requires access to human embryos which has 
raised questions about whether or not a human embryo constitutes a human life and thereby 
requires appropriate protection and safeguards and if research on embryos is allowed, then under 
which circumstances can they be procured – e.g. should women and men be allowed to donate 
gametes for research purposes, should it be permissible to create embryos purely for research 
purposes, should hESC research only be carried out on so-called ‘leftover embryos’ from infertility 
treatment? One of the liveliest discussions in the course of our project took place in Shanghai 
when participants at our stem cell workshop discussed the moral status of a human embryo. 
Throughout the world, different countries have different legal positions on whether or not it 
should be permissible to carry out research on human embryos – some countries prohibit it while 
others allow it under specific conditions. 
 
The discussion quickly centred on the question of when a human life begins – is it at the moment 
of fertilization (when egg and sperm mix), nidation (when an early embryo implants into the 
uterus), perception of ‘primitive streak’ (a structure in the embryo that becomes visible under the 
microscope around fourteen days after fertilisation) or birth? While the discussion was very 
technical concerning the biology of reproductive processes, it was clear that the answer to 
whether or not, or at which point, a human embryo constitutes a human life would not come from 
biology: “Ethical standards stem from cultural and religious background and they are highly 
diversified among different regions and countries.” Some presenters suggested that in China a 
traditional Confucian view still prevailed and that the “governance of biotechnology and 
biomedical research should be exclusively based on unique Chinese culture, e.g. Confucian values 
and principles”. According to Confucian principles, it was argued, “a person begins with birth and 
ends with death… and is an entity which has the capacity for social relationship” although “a 
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human embryo is a human biological life, a precursor of person, not merely ‘stuff’ like placenta… 
so it deserves due respect: if there is no sufficient reason, it should not be permitted to 
manipulate or destroy it”. Another participant pointed out that this view was very much in line 
with the United Kingdom’s Warnock Committee who have suggested that there should be a 
“gradation in the respect accorded to a foetus as it develops from zygote to early embryo to its 
birth”, although in Germany full moral status was accorded by the Embryo Protection Act to “any 
fertilized human oocyte after that point in time at which the pronuclei have fused, any later stage 
of its development and to any totipotent parts which could, under the proper circumstances, be 
able to develop into an individual being”. 
 
What this exchange between workshop participants gave insight into was precisely a negotiation 
of difference, however caricatured. What was it that counted as a Chinese, German or UK ‘position’ 
or view on the moral status of the embryo and how might such a view be ‘established’? In the 
discussions that followed various processes for establishing a national position were discussed, 
including: public opinion polls, existing laws or law proposals and national Ethics Commissions. 
There was no clear answer to this latter question, rather various options were identified, though 
workshop participants did arrive at a conclusion: “each culture must find the right mix of biology, 
theology and metaphysics to satisfy it – to fit with its cultural narrative. ‘Drawing the line’ it seems 
paradoxically, [i]s both arbitrary and essential”. 
 
These kinds of discussion concerned ethical oversight of biomedical and biological research from a 
national point of view – a kind of national stewardship of biotech science. The questions of what 
forms of manipulation and disposal of early human life should or should not be allowed could not 
be answered within the confines of a laboratory, but rather required the involvement of other 
experts, members of the public, government officials, etc. Yet it was up to each country to 
organise the ways in which their respective inputs would be fed into the crystallising of some kind 
of a national position or ‘consensus’. Notwithstanding the fact that multiple positions on the moral 
status of a human embryo might be found within a nation’s borders, the conclusion amongst 
workshop participants seemed to be that this fell within a national remit. It should be pointed out 
that Chinese regulations do allow, as do UK regulations, research on human embryos up to 
This paper has been accepted for publication in Third World Quarterly, and the final (edited, 
revised and typeset) version of this paper will be published in TWQ 33(4), 2012 by Taylor & 
Francis 
 
 
fourteen days after fertilisation and both countries are therefore described as having ‘permissible’ 
stem cell regulation which adds to their ‘attraction’ as global sites of stem cell research. 
 
‘Cultural sensitivity’ in the recruitment of volunteers 
 
Once a biomedical research project proposal has been ethically and peer reviewed and thereby 
funded, the everyday work of the principal investigators and/or clinicians begins. Research staff 
has to be hired and trained, informed consent protocols have to be designed and modified to fit 
target patients, recruitment efforts have to be put in motion and follow-up procedures have to be 
agreed upon. It is precisely this moment – when researchers and clinicians must interact with 
potential participants in biomedical research – that is considered ethically precarious. It is at this 
moment that possibilities for coercion, exploitation, inducement and undue influence emerge, 
which could be driven by commercial motives, personal career advancement considerations, lack 
of healthcare services in resource-poor settings, etc. 
 
What I found during the course of our many workshops and conferences was that regardless of 
the type of biomedical research that was under scrutiny (stem cell research, biobanking or clinical 
trials), there seemed to be an ongoing negotiation around the precise form that interaction 
between researchers and potential research subjects should take place, depending on the 
particular context ‘on the ground’. And one element of this context was the particular ‘culture’ 
that the research was to take place in. Let me show how by discussing the way in which the 
question of informed consent in the context of clinical trials and biobanking was debated by 
participants from China and Europe. 
 
Ever since the Nuremberg code from 1949 insisted that when it comes to recruiting participants 
for medical research “the voluntary consent of the human subject is absolutely essential”21, one of 
the most prominent tools to have been developed for ensuring that interaction between 
researchers and potential participants is ethical and appropriate has been the informed consent 
procedure/form. The conversation between researcher and potential participant, the form which 
explains the research, and the signature of the potential participant on that form are meant to 
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ensure voluntariness as well as symbolise respect for a person. As already noted, there is a vast 
literature on the shortcomings of such formalised approach to bioethics, what I will discuss here 
instead is how workshop participants argued for an adjustment of this process so as to fit a 
particular cultural and socio-economic context. So what kind of a ‘Chinese context’ could be 
discerned from the debates at our workshops? 
 
I would point to two particular areas related to: 1) who has the authority to consent; 2) how to 
recruit in a climate of commercialisation. One of the assumptions behind the idea of genuine 
voluntary informed consent is autonomy – individuals are the ones who should be deciding 
whether he or she would like to participate in biomedical research as symbolised in the signature. 
The spectre of ‘many Chinas’ once again emerged in discussions about whether such an 
individualised approach to consent is at all relevant or realistic in certain contexts. Some speakers 
argued that since any kind of interaction with hospitals (whether for treatment or participation in 
medical research) in China had some kind of financial implications, then any decisions would 
always be taken up in the context of families, with heads of households often having a final say. 
Moreover, in the context of large scale biobanking projects requiring thousands of volunteers, for 
example from a particular ethnic community, consent would never be merely individual, as village 
leaders and other community heads would often have to sanction any kind of large scale medical 
research in their communities22. So there were certain circuits of authority that needed to be 
followed if medical research was to be made ethical in a particular context. And although such 
distinctions tend to caricaturise, many speakers pointed to a collectivist China vs. an individualist 
Europe as an important difference that it was crucial to take into account when adapting 
recruitment and informed consent procedures into Chinese contexts. Indeed BIONET’s Expert 
Group23 ended up recommending that “before any research collaborations [between Chinese and 
European researchers] are approved or begin, participating researchers must receive training on 
how potential research participants are to be engaged with, as well as on how informed consent is 
to be obtained, while focusing on the particularities of the kind of research at stake… as well as 
the socioeconomic and cultural context.”24 
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Secondly, as anyone with a minimum of interest in health care issues within China will know, over 
the last two decades medical care has come to be commercialised as collective insurance systems 
have been overtaken by individualised healthcare plans and out-of-pocket medical service fees. At 
many of our workshops clinicians would highlight the problems that this had brought in its wake, 
in particular as regards a worsening of doctor-patient relations: increasing corruption as the only 
means of ensuring access to good quality care; decreasing trust between doctors and patients; 
increasing litigation against doctors and hospitals; an epidemic of violence directed at doctors and 
nurses; and more. Recruiting potential research participants in such a climate raises particular 
challenges, which many workshop participants from China argued need to be taken into account in 
the planning and carrying out of medical research. For example, one speaker suggested that 
“patients, physicians/ investigators and health care administrators regularly confuse clinical trials 
with medical care” and that “some physicians/investigators seem deliberately to treat clinical trials 
as medical care”. The fact was that participating in medical research could “save patients and their 
families from heavy economic burdens”. In such a climate of commercialisation, another 
participant argued that “instead of empowering, informed consent can be disempowering if 
donors do not have the ability to nurture, sustain and develop themselves”. And so the 
particularities of China’s health care system in the 21st century raised challenges for the ethical 
governance of biomedical research which had to be addressed. 
 
The kinds of discussions I have briefly summarised here concerned oversight of interaction 
between researchers and potential research subjects as a way of minimising risks of exploitation, 
undue influence and coercion. While not all were agreed on exactly how, there was some kind of 
agreement among many workshop and conference participants that the ways in which such 
interaction should be structured, organised, carried out and monitored needed to be adapted to a 
‘Chinese’ context which was circumscribed in terms of culture as well as socio-economic 
stratification. It was through such differentiation – that required establishing the particularities of 
that which makes up Chinese contexts – that the ethical governance of biomedical research could 
be ensured. So in this sense differentiating was what would allow the adaptation of the universal 
to the particular. In the words of one workshop participant: “Basic values, such as respect, non-
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maleficence/beneficence and justice are shared by Western and Eastern cultures alike… though as 
Confucius said, ‘By nature men are similar; by practice men are wide apart’. 
 
Conclusion 
 
In this article I have demonstrated how difference organises global negotiations about how to 
ensure that biotechnological research in a time of increasing global mobility is ‘ethical’. On the one 
hand, difference is mobilised in such negotiations as a way to carve out certain competitive 
advantages that make a particular nation – such as China or the United Kingdom – an ‘attractive’ 
place to carry out biomedical research. On the other hand, difference is invoked to insist that 
institutionalised, ‘universal’ bioethical tools – such as national ethics committees, declarations, 
ethical review boards or informed consent procedures – be adapted to particular cultural, socio-
economic contexts. That is to say, difference matters in global biotechnology 
 
Much has been made of the emancipatory potential of difference in the mobilization strategies of 
marginalised groups against dominant narratives, groups or sets of actors as a way of “dissolving 
some of the strong structures of Euro-modernity at the level of theory by favoring flat alternatives; 
positing the fact that epistemic differences can be – indeed are – grounds for the construction of 
alternative worlds”25. What I have shown here is that difference can also be actively mobilised in 
those ‘dominant’ settings, as particular strategies of nation-building. By focusing on a specific 
forum of global negotiation – a three-year collaborative project between European and Chinese 
experts on the ethical governance of biomedical and biological research – I showed how difference 
organised the terms of debate among participants. In this sense, difference can be a leveller in 
that rather than invoking a universal global bioethics system it authorises multiplicity thereby 
invoking the particular. Hence, by shifting analytical focus to the governing of difference we are 
able to see the multiple ways in which it can be mobilised in various contexts – whether among 
marginalised groups or dominant sectors of society. 
 
In the foregoing, I have not attempted to explain or account for differences between for example 
China and the United Kingdom, rather I have honed in on those occasions where difference was 
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actively made through global negotiations between European and Chinese scientists, clinicians, 
experts and others. Such mobilisations of difference played their part in the kinds of nation-
building strategies that seek to establish a certain country as a global ‘biotech power’.  
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